GlassScriptPhysician profile
Marilyn C Moss
NPI 1962405126
$2,719.21
in general payments reported to CMS, 2019-2025
26 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $189 · 2021: $448 · 2022: $552 · 2023: $464 · 2024: $416 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $448.23 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $391.30 | 2020-2024 | Perseris, Sublocade |
| Otsuka America Pharmaceutical, INC. | $271.13 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Novo Nordisk INC | $206.66 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $193.16 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $176.06 | 2019-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Lilly USA, LLC | $148.08 | 2019-2023 | Mounjaro |
| Braeburn INC. | $132.15 | 2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $123.34 | 2019-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.79 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $74.20 | 2021-2023 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $71.01 | 2019-2020 | |
| Axsome Therapeutics, INC. | $53.87 | 2025 | Auvelity |
| Paratek Pharmaceuticals, INC. | $50.86 | 2021-2023 | Nuzyra |
| Vanda Pharmaceuticals INC. | $37.74 | 2024 | Fanapt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34.92 | 2021-2023 | Shingrix |
| Abbott Laboratories | $34.57 | 2023-2024 | Freestyle Libre 3 |
| Soleno Therapeutics, INC. | $29.51 | 2025 | Vykat Xr |
| Sunovion Pharmaceuticals INC. | $29.16 | 2020-2021 | |
| Exact Sciences Corporation | $28.18 | 2025 | Cologuard Collection Kit |
| Noven Therapeutics, LLC | $23.23 | 2025 | Xelstrym |
| Lundbeck LLC | $23.02 | 2024 | Rexulti |
| Uswm, LLC | $18.94 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.41 | 2022 | |
| Allergan, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.